MetaCap

Cardio Diagnostics Holdings Inc. (CDIO)

NASDAQ: CDIOHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD

1.60-0.05 (-3.03%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CDIO stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$2.52
52-week range
0.97 – 7.91
Day range
1.53 – 1.68
Volume / Avg
32.03K / 26.91K
Beta
—

52-week range

$0.97$7.91

CDIO stock today

Cardio Diagnostics (CDIO) closed at $1.60 on Nov 20, down 3.03% (-$0.05), versus the S&P 500's 3.70% decline. Shares are 79.8% below their 52-week high of $7.91 and 64.9% above the 52-week low of $0.97, near the bottom of the past year's range. Cardio Diagnostics has posted a net loss over the last twelve months (EPS of -$2.52), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Cardio Diagnostics

Company profile

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management.

Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
CEO
Dr. Meeshanthini V. Dogan Ph.D.
Headquarters
Chicago, IL
Employees
15
IPO year
2022
Website
cdio.ai

Financial highlights

Full financials

In fiscal 2025, Cardio Diagnostics generated $14,825 in revenue, down 57.5% from fiscal 2024, the first decline in the 5 years shown. Cardio Diagnostics reported a net loss of $6.5 million, compared with a loss of $8.4 million a year earlier. Operating margin was -43737.5%.

Cardio Diagnostics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$14.82K$34.89K$17.07K$950$901
Growth-57.51%+104.45%+1696.32%+5.44%—
Net income$-6.50M$-8.38M$-8.38M$-4.66M$-620.45K
EPS (diluted)$-3.71$-9.35$-0.66$-1.51$-0.53

Earnings

Earnings history
Last reported (Sep/2026)
Nov 6, 2026
EPS actual vs est.
$-0.59 vs —

Cardio Diagnostics peers

Health Care sector
CDIO peer companies
CompanyPrice% ChgMarket capCompare
BMRABiomerica Inc.1.08-0.92%$4.97Mvs CDIO
TRIBTrinity Biotech plc ADR6.24+13.76%$5.07Mvs CDIO
VNRXVolitionRX Limited0.1621-1.58%$5.85Mvs CDIO
QCLSQ/C Technologies Inc.0.2784-6.01%$2.40Mvs CDIO
VRAXVirax Biolabs Group Limited0.3319-12.89%$446.40Kvs CDIO
IMDXInsight Molecular Diagnostics Inc.1.97+18.67%$80.88Mvs CDIO
ICCCImmuCell Corporation10.92-2.41%$99.28Mvs CDIO
NNNNAnbio Biotechnology Class A3.32-9.04%$145.72Mvs CDIO

Indexes, lists and sector

Cardio Diagnostics stock FAQ

What is Cardio Diagnostics's stock price today?

CDIO last traded at $1.60 as of Nov 20, 4:00 PM EST, down 3.03% on the day. Prices are delayed at least 15 minutes.

Who is Cardio Diagnostics's CEO?

Dr. Meeshanthini V. Dogan Ph.D. is the chief executive officer of Cardio Diagnostics Holdings Inc., which has about 15 employees.

What is the CDIO 52-week high?

The 52-week high for CDIO is $7.91 and the 52-week low is $0.97. The stock is currently 79.8% below its high.

Compare CDIO